Enavogliflozin - Daewoong
Alternative Names: Dapagliflozin; DWP-16001; DWP16001 drug A; DWP16001 drug B; DWP16001 drug C; Envlo; ODP 9401Latest Information Update: 24 Feb 2026
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihypercalcaemics; Antihyperglycaemics; Benzofurans; Cyclopropanes; Heart failure therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Heart failure
Most Recent Events
- 07 Jan 2026 Daewoong Pharmaceutical completes a phase I trial in healthy volunteers in South Korea (PO) (NCT07213310)
- 09 Nov 2025 Daewoong Pharmaceutical initiates a phase I trial in healthy volunteers in South Korea (PO) (NCT07213310)
- 08 Oct 2025 Daewoong Pharmaceutica plans a phase I PK trial (In volunteers) in South Korea (PO, Tablets) in November 2025 (NCT07213310)